Amarillo Biosciences, Inc. AMAR Company Overview Stock

New Post Public Reply Private Reply Replies (0) Message Board

Sep 13, 2013 at 2:44 PM

Amarillo Biosciences, Inc. AMAR Company Overview

Stock Message Board http://investorshangout.com/search?q=AMAR&...mp;yt1=Go!

Amarillo Biosciences, Inc. AMAR Current Price and Quotes
Last Price 0.018
Previous Close 0.018 Open 0.018
Daily Range 0.018 - 0.018 52wk Range 0.047 - 0.0116
Volume 4,400 Dividend N/A
Average Vol (3m) 41,652 Yield N/A
Amarillo Biosciences, Inc. AMAR
Company Information

4134 Business Park Drive
Amarillo, TX 79110

Website: http://www.amarbio.com
Phone: (806) 376-1741

Amarillo Biosciences, Inc. AMAR
Not Available

Amarillo Biosciences, Inc. AMAR
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Jun 30, 2013 10-Q
CIK 0001014763
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: TX, USA
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts

Joseph Cummins President, CEO, CFO
Company Directors

Not Available
Service Providers

Auditor/Accountant
Not Available
Legal Counsel
Not Available
Investor Relations Firm
Not Available

Amarillo Biosciences, Inc. AMAR
AMAR Security Details

Share Structure

Market Value1 $1,319,238 a/o Sep 12, 2013
Shares Outstanding 73,291,008 a/o Aug 08, 2013
Float Not Available
Authorized Shares Not Available
Par Value 0.01
Shareholders

Shareholders of Record 1,940 a/o Apr 19, 2012
Security Notes

New Issue=8-96 2,000,000 shs at $5 by Whale Securities Co., L.P.
Short Selling Data

Short Interest 100 (0%)
Aug 30, 2013
Significant Failures to Deliver No
Transfer Agent(s)

American Stock Transfer & Trust Company

Amarillo Biosciences, Inc. AMAR Recent News

Amarillo Biosciences, Inc. AMAR Financials
Period Ending Dec 31, 2012 Dec 31, 2011 Dec 31, 2010 Dec 31, 2009
Total Revenue 1 58 5 52
Cost of Revenue - 4 3 26
Gross Profit - 54 2 26
Operating Expenses

Research and Development 200 281 433 465
Sales, General and Admin. 355 919 638 1,203
Non-Recurring Items - - - -
Other - - - -
Operating Income (555) (1,146) (1,069) (1,641)
Income From Continuing Operations

Add'l Income/Expense Items 59 44 1,670 (1,237)
Earnings Before Interest and Tax (495) (1,102) 600 (2,878)
Interest Expense 156 212 94 93
Earnings Before Tax (651) (1,314) 506 (2,971)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (651) (1,314) 506 (2,971)
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (651) (1,314) 506 (2,971)
Preferred Stock and Other Adjustments (31) (17) (4) -
Net Income Applicable to Common Shareholders (682) (1,331) 502 (2,971)

AMAR Amarillo Biosciences, Inc. Research DD Guide

AMAR Amarillo Biosciences, Inc. Stock Message Board http://investorshangout.com/search?q=AMAR&...mp;yt0=Go!
AMAR Amarillo Biosciences, Inc. Stock Quote http://www.otcmarkets.com/stock/AMAR/quote
AMAR Amarillo Biosciences, Inc. Stock Chart http://www.otcmarkets.com/stock/AMAR/chart
AMAR Amarillo Biosciences, Inc. Company Info http://www.otcmarkets.com/stock/AMAR/company-info
AMAR Amarillo Biosciences, Inc. Recent News http://www.otcmarkets.com/stock/AMAR/news
AMAR Amarillo Biosciences, Inc. Financials http://www.otcmarkets.com/stock/AMAR/financials
AMAR Amarillo Biosciences, Inc. Filings and Disclosure http://www.otcmarkets.com/stock/AMAR/filings
AMAR Amarillo Biosciences, Inc. Short Sales http://www.otcmarkets.com/stock/AMAR/short-sales
AMAR Amarillo Biosciences, Inc. Insider Disclosure http://www.otcmarkets.com/stock/AMAR/insider-transactions
AMAR Amarillo Biosciences, Inc. Research Reports http://www.otcmarkets.com/stock/AMAR/research
AMAR Amarillo Biosciences, Inc. Summary http://finance.yahoo.com/q?s=AMAR
AMAR Amarillo Biosciences, Inc. Historical Prices http://finance.yahoo.com/q/hp?s=AMAR+Historical+Prices
AMAR Amarillo Biosciences, Inc. Interactive Chart http://finance.yahoo.com/echarts?s=AMAR
AMAR Amarillo Biosciences, Inc. Basic Chart http://finance.yahoo.com/q/bc?s=AMAR+Basic+Chart
AMAR Amarillo Biosciences, Inc. Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=AMAR+Basic+Tech.+Analysis
AMAR Amarillo Biosciences, Inc. Headlines http://finance.yahoo.com/q/h?s=AMAR+Headlines
AMAR Amarillo Biosciences, Inc. Press Releases http://finance.yahoo.com/q/p?s=AMAR+Press+Releases
AMAR Amarillo Biosciences, Inc. Company Profile http://finance.yahoo.com/q/pr?s=AMAR+Profile
AMAR Amarillo Biosciences, Inc. Key Statistics http://finance.yahoo.com/q/ks?s=AMAR+Key+Statistics
AMAR Amarillo Biosciences, Inc. Industry http://finance.yahoo.com/q/in?s=AMAR+Industry
AMAR Amarillo Biosciences, Inc. Major Holders http://finance.yahoo.com/q/mh?s=AMAR+Major+Holders
AMAR Amarillo Biosciences, Inc. Insider Transactions http://finance.yahoo.com/q/it?s=AMAR+Insider+Transactions
AMAR Amarillo Biosciences, Inc. Insider Roster http://finance.yahoo.com/q/ir?s=AMAR+Insider+Roster
AMAR Amarillo Biosciences, Inc. Income Statement http://finance.yahoo.com/q/is?s=AMAR
AMAR Amarillo Biosciences, Inc. Balance Sheet http://finance.yahoo.com/q/bs?s=AMAR
AMAR Amarillo Biosciences, Inc. Cash Flow http://finance.yahoo.com/q/cf?s=AMAR+Cash+Flow&annual
AMAR Amarillo Biosciences, Inc. Nasdaq http://www.nasdaq.com/symbol/AMAR
AMAR Amarillo Biosciences, Inc. Market Watch http://www.marketwatch.com/investing/stock/AMAR
AMAR Amarillo Biosciences, Inc. Bloomberg http://www.bloomberg.com/quote/AMAR:US
AMAR Amarillo Biosciences, Inc. Morningstar http://quotes.morningstar.com/stock/s?t=AMAR
AMAR Amarillo Biosciences, Inc. Bussinessweek http://investing.businessweek.com/research/st...icker=AMAR
AMAR Amarillo Biosciences, Inc. Barchart http://www.barchart.com/quotes/stocks/AMAR
AMAR Amarillo Biosciences, Inc. OTC Short Report http://otcshortreport.com/index.php?index=AMAR
AMAR Amarillo Biosciences, Inc. Investopedia http://www.investopedia.com/markets/stocks/AMAR/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MetroScape: Local Roots Fuel Bold DFW Growth Plans

A Local Business with Big Aspirations Here's the deal, folks: Local guys Dr. Marc Nickell and Chris Brewer snatched up MetroScape Landscape like it was the last slice of grandma's pie. Why? Not just for the greenbacks—they're putting down roots in their very own backyard, the Dallas-Fort Worth area. What Does Local Really Mean? Look, it's one thing hitting up a...

Fidelis Care Opens $120K Workforce Grants for Aid

Fidelis Care Steps Up Workforce Engagement Fidelis Care's latest move introduces a fresh shot at tackling two birds with one stone—economic and health stability for Medicaid members. The Workforce Pathways to Health and Economic Mobility grants present up to $120,000 in support for New Yorkers, an attempt aimed squarely at reducing the vicious cycle that traps many in...

Milwaukee Art Museum Secures $10 Million Preservation Fund

In a world where art meets aspiration, the Quadracci family’s latest $10 million gift to the Milwaukee Art Museum speaks volumes. With a vision to guarantee the future of architectural elegance, they’re making sure Santiago Calatrava’s stunning Quadracci Pavilion remains a cornerstone on Milwaukee’s skyline. For twenty-five years, this striking creation has not...

J.H. Strain & Sons' Asset Sale Seals a New Era

Texan Legacy Bows Out of the Asphalt Game Here's a fresh chapter in the world of road construction that'll have folks in the industry doing a double-take. Elder Bray & Bankler, a bigwig among corporate law circles, has been guiding this tale. They've shepherded J.H. Strain & Sons through selling off its asphalt manufacturing and construction assets to none other than...

Greentown Labs Builds Momentum in Climate Innovation

Paving the Way for Climate-Tech Pioneers Ah, Massachusetts—where the perfect storm of bright minds and groundbreaking innovation is brewing. It's not all just Harvard and MIT. It's programs like Greentown Labs' First Valley Fellowship stirring the pot, ushering in a new era of climate and energy startups. We're talking a robust second year for the Fellowship, where...

Housing Transition: Unlocking the Trillion-Dollar Pathway

A Trillion-Dollar Balancing Act at COP31 The housing market: one giant balancing act, now with a trillion bucks at stake. The Sustainable Real Estate Forum (SREF) didn't hold back in their new white paper, "The Trillion-Dollar Housing Transition." They've outlined the monumental shift needed to get our housing not just affordable, but sustainable too. The Lay of the Land...

Quad Sees Marginal Gains Amid Industry Challenges

Treading Water with a Splash of Strategic Moves When you're in the thick of market shifts, sometimes it's not about big leaps but staying afloat with purpose. That's what Quad's recent financial release seems to hint at. A steady net sales figure hovering at $587 million for Q3 2026, barely a nudge compared to last year's numbers, sets the tone. It's not the fireworks...

Corgi Insurance Eyes $100B Auto Market with New Launch

Leaping Into a Booming Market Well, it looks like someone lit a fire under Corgi Insurance, and they're ready to chase bigger bones. They’ve just rolled out a product called Corgi Business Auto, signaling quite a bold move into the hefty, nearly $100 billion U.S. commercial auto insurance arena. Now, as an old hand at this game, my ears perk up whenever I see a player...

Mission Wealth's Rising Stars Shine Bright in 2026

The financial world can be a ruthless arena, especially when you're under 40 and trying to make your mark. But in 2026, two up-and-comers from Mission Wealth are doing just that—earning spots on the coveted InvestmentNews Rising Stars list. Spotlight on Kulha and Dragan Andrew Kulha, with his legal and financial acumen, breaks down estate strategies like a seasoned...

UPM Defies Market Challenges: Strong Q3 Cash Flow

UPM's Impressive Q3 Performance Amidst Challenges UPM-Kymmene Corporation just dropped their Q3 numbers, and let me tell ya, there's a lot to digest. In the face of some pretty gnarly market conditions—think destocking and those pesky cost inflations—they've managed to pull a rabbit out of the hat with strong cash flow. That's not a small feat, folks; it's a damn...